Related Experiment Videos
[Possible cardiotoxicity induced by orally administered fluoropyrimidines]
1Servicio de Medicina Interna, Hospital General Universitario, Valencia.
Anales De Medicina Interna (Madrid, Spain : 1984)
|October 1, 1990
Summary
Four additional cases of cardiotoxicity linked to 5-fluorouracil (5-FU) or oral fluoropyrimidines like Ptorafur and UFT were observed. These cases highlight potential myocardial ischemia and EKG changes in patients without prior heart conditions.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Fluoropyrimidines, including 5-fluorouracil (5-FU), Ptorafur, and UFT, are widely used chemotherapy agents.
- Cardiotoxicity is a known but not fully understood side effect of these drugs.
- The incidence and specific manifestations of cardiotoxicity in patients without pre-existing cardiac conditions warrant further investigation.
Observation:
- Four new cases of cardiotoxicity associated with 5-FU or oral fluoropyrimidines (Ptorafur, UFT) are reported.
- Patients generally had no history of heart disease, with one exception.
- Observed toxicities included myocardial ischemia and electrocardiogram (EKG) changes in three patients with measured cardiac enzymes.
Findings:
- The study presents additional evidence linking 5-FU and oral fluoropyrimidines to cardiotoxicity.
- Myocardial ischemia and EKG abnormalities are key indicators of this drug-induced toxicity.
- The findings underscore the importance of monitoring cardiac function during treatment with these agents.
Implications:
- Increased awareness among clinicians regarding the potential for cardiotoxicity from 5-FU and oral fluoropyrimidines, even in patients without prior heart disease.
- The need for vigilant cardiac monitoring and prompt management strategies for patients receiving these chemotherapeutics.
- Further research into the etiopathogenesis and predictive markers of fluoropyrimidine-induced cardiotoxicity is crucial for improving patient outcomes.